Animal models of breast cancer: Their diversity and role in biomedical research

Breast Cancer Research and Treatment

Volumn 39, Issue 1, 1996, Pages 1-6

  Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE;

ANIMAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR XENOGRAFT;

ANIMAL WELFARE; ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC;

EID: 0029991480     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806073     Document Type: Short Survey

References (27)

1. Clarke R, Dickson RB, Lippman ME: Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12: 1-23, 1992
2. Clarke R, Lippman ME: Antiestrogen resistance: mechanisms and reversal. In: Teicher BA (ed) Drug Resistance in Oncology. Marcel Dekker, New York, 1992, pp 501-536
3. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Brünner N: Hormone resistance, invasiveness and metastatic potential in human breast cancer. Breast Cancer Res Treat 24:227-239, 1993
4. Russo J, Russo IH: Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39:7-20, 1996 (this issue)
5. Smith GH: Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res Treat 39:21-31, 1996 (this issue)
6. Javier R, Shenk T: Mammary tumors induced by adenovirus type-9: a role for the viral early region 4 gene. Breast Cancer Res Treat 39:57-67, 1996 (this issue)
7. Fluck MM, Haslam SZ: Mammary tumors induced by polyoma virus. Breast Cancer Res Treat 39:45-56, 1996 (this issue)
8. Callahan R: MMTV induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Breast Cancer Res Treat 39:33-44, 1996 (this issue)
9. Clarke R: Human breast cancer cell line xenografts as models of breast cancer: the immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39:69-86, 1996 (this issue)
10. Brünner N, Spang-Thomsen M, Cullen K: The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39:87-92, 1996 (this issue)
11. Price JE: Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 39:93-102, 1996 (this issue)
12. Amundadottir LT, Merlino G, Dickson RB: Transgenic mouse models of breast cancer. Breast Cancer Res Treat 39:119-135, 1996 (this issue)
13. Zhang R, Haag JD, Gould MN: Reduction in the frequency of activated ras oncogenes in rat mammary carcinomas with increasing N-methyl-N-nitrosourea doses or increasing prolactin levels. Cancer Res 50:4286-4290, 1990
14. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689, 1989
15. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models for angiogenesis and metastasis. Breast Cancer Res Treat 39:103-117, 1996 (this issue)
16. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
17. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in athymic nude mice: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196, 1987
18. Belani CP, Pearl P, Whitley NO, Aisner J: Tamoxifen withdrawal response: report of a case. Arch Intern Med 149:449-450, 1989
19. Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet i:36, 1989
20. Stein W, Hortobagyi GN, Blumenschein GR: Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 22:45-46, 1983
21. Gottardis MM, Wagner RJ, Borden EC, Jordan CV: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765-4769, 1989
22. Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L: Estrogen and antiestrogen modulation of mouse natural killer activity and large granular lymphocytes. Cell Immunol 106:191-202, 1987
23. Seaman WE, Blackman MA, Gindhart TD, Roubinian JR, Loeb JM, Talal N: β-estradiol reduces natural killer cells in mice. J Immunol 121:2193-2198, 1978
24. Hanna N, Schneider M: Enhancement of tumor metastases and suppression of natural killer cell activity by β-estradiol treatment. J Immunol 130: 974-980, 1983
25. Seaman WE, Talal N: The effect of 17β-estradiol on natural killing in the mouse. In: Herberman RB (ed) Natural Cell-Mediated Immunity against Tumors. Academic Press, New York, 1980, pp 765-777
26. Berry J, Green BJ, Matheson DS: Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminogluthemide. Cancer Immunol Immunother 24:72-75, 1987
27. Bae S-N, Arand G, Azzam H, Pavasant P, Torri J, Frandsen TL, Thompson EW: Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res Treat 24:241-255, 1993